T. Hazendonk

Antigenic and immunogenic properties of inactivated polio vaccine made from Sabin strains.

C. Beuvery, G. Kersten, T. Hazendonk, 1999, Vaccine.

Restored functional immunogenicity of purified meningococcal PorA by incorporation into liposomes.

W. Hennink, W. Jiskoot, D. Crommelin, 2003, Vaccine.

Monoclonal Antibodies to Polioviruses

A. Osterhaus, A. L. Wezel, T. Hazendonk, 1981 .

Monoclonal antibodies to polioviruses. Comparison of intratypic strain differentiation of poliovirus type 1 using monoclonal antibodies versus cross-absorbed antisera.

A. Osterhaus, A. V. van Wezel, F. Uytdehaag, 1983, Intervirology.

Comparison of four bifunctional reagents for coupling peptides to proteins and the effect of the three moieties on the immunogenicity of the conjugates.

E. C. Beuvery, G. I. Tesser, T. Hazendonk, 1989, Journal of immunological methods.

A new WHO International Reference Reagent for use in potency assays of inactivated poliomyelitis vaccine.

E. C. Beuvery, A. Heath, G. Kersten, 1997, Biologicals : journal of the International Association of Biological Standardization.

Induction of neutralizing antibodies by poliovirus capsid polypeptides VP1, VP2 and VP3.

M. Henneke, A. V. van Wezel, T. Hazendonk, 1983, Vaccine.

In vitro determination of antigen quality: biosensor analysis and fluorescence spectroscopy.

E. C. Beuvery, W. Jiskoot, G. Kersten, 1998, Developments in biological standardization.

Monoclonal antibodies to polioviruses. Production of specific monoclonal antibodies to the Sabin vaccine strains.

A. Osterhaus, A. V. van Wezel, T. Hazendonk, 1981, Intervirology.